INVIVO CREVICULAR LEUKOCYTE RESPONSE TO A CHEMOTACTIC CHALLENGE - INHIBITION BY EXPERIMENTAL DIABETES
INVIVO CREVICULAR LEUKOCYTE RESPONSE TO A CHEMOTACTIC CHALLENGE - INHIBITION BY EXPERIMENTAL DIABETES
复制标题
DOI：
10.1128/iai.37.3.1013-1020.1982
复制
发表时间：
1982-01-01
影响因子：
3.1
通讯作者：
RAMAMURTHY, NS
中科院分区：
文献类型：
--
作者：
GOLUB, LM;NICOLL, GA;RAMAMURTHY, NS
大鼠糖尿病抑制中性粒细胞迁移到愈合的龈沟，这一作用与体外中性粒细胞趋化活性受损有关。最近，在体内的人和大鼠的龈沟中性粒细胞的趋化性的挑战，并在本研究中使用链脲佐菌素诱导的糖尿病大鼠的这种测定。在测量静息中性粒细胞计数后，将最佳浓度的2种趋化剂，酪蛋白（0.2 μ l，2 mg/ml）或N-甲酰乙硫酰亮氨酰苯丙氨酸（0.2 μ l，10-4 M）置于对照和糖尿病大鼠的龈缝中（时间零点）。延迟15分钟后，每5分钟评估一次中性粒细胞计数和牙龈沟液流量，持续0.5小时。对照组大鼠（n = 14）显示中性粒细胞计数增加，在N-甲酰甲硫氨酰亮氨酰苯丙氨酸激发后30分钟达到最大水平（中性粒细胞峰值反应），5分钟后急剧下降。糖尿病4天（n = 4）、14天（n = 8）和20天（n = 5）分别使中性粒细胞反应峰值降低45、66或71%。酪蛋白在对照组大鼠中产生与N-甲酰甲硫氨酰亮氨酰苯丙氨酸相同的反应。持续20天的不受控制的糖尿病使中性粒细胞对酪蛋白的峰值反应降低了83%;每天服用胰岛素的糖尿病患者仅降低了34%。龈沟液对化学引诱物的反应模式与中性粒细胞反应相反。用琼脂糖凝胶法测定了大鼠腹腔中性粒细胞的体外趋化活性，并与体内趋化反应呈显著正相关（r = 0.84; P < 0.01）。如果在糖尿病患者（或其他与白细胞功能障碍相关的全身性疾病）中观察到相同的体内缺陷，则该测试可能有助于诊断，以快速评估中性粒细胞趋化性，代替体外试验，并确定异常易患侵袭性牙周病的患者。
Diabetes in rats inhibits the migration of neutrophils into the healing gingival crevice, an effect associated with impaired in vitro neutrophil chemotactic activity. Recently, the in vivo response of human and rat crevicular neutrophils to a chemotactic challenge was described and this assay was used in the present study on streptozotocin-induced diabetic rats. Optimal concentrations of 2 chemotactic agents, casein (0.2 .mu.l, 2 mg/ml) or N-formylethionylleucylphenylalanine (0.2 .mu.l, 10-4 M), were placed into the gingival crevices of control and diabetic rats (time zero) after the resting neutrophil count was measured. After a 15-min delay, the neutrophil counts and gingival crevicular fluid flow were assessed every 5 min for another 0.5 h. The control rats (n = 14) showed an increase in neutrophil counts which reached maximum levels 30 min after the N-formylmethionylleucylphenylalanine challenge (peak neutrophil response) and decreased dramatically 5 min later. Diabetes of 4 days (n = 4), 14 days (n = 8), and 20 days (n = 5) duration reduced the peak neutrophil response 45, 66 or 71%, respectively. Casein produced the same response as N-formylmethionylleucylphenylalanine in control rats. Uncontrolled diabetes of 20 days duration reduced the peak neutrophil response to casein by 83%; diabetics administered insulin on a daily basis showed a reduction of only 34%. The pattern of change in gingival crevicular fluid flow in response to chemoattractants paralleled the neutrophil response. The chemotactic activity of peritoneal neutrophils was assessed in vitro with the agarose gel technique and was found to be correlated (r = 0.84; P < 0.01) with the in vivo chemotactic response in the same rats. If the same in vivo defect is observed in humans with diabetes (or with other systemic diseases associated with leukocyte dysfunction), this test could be useful diagnostically to rapidly assess neutrophil chemotaxis in lieu of in vitro assays and to identify patients who are unusually susceptible to aggressive periodontal disease.